Show Summary Details
Page of

Adjuvant chemotherapy 

Adjuvant chemotherapy
Adjuvant chemotherapy

Uschi Hofmann

, Fiona Collinson

, Peter Hall

, Mike Braun

, and Daniel Swinson

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 24 June 2021

Adjuvant single agent fluoropyrimidine (Fu) reduces the relative risk of death following potentially curative surgery by 20–30%. Addition of oxaliplatin reduces relative risk by a further 15%

The risk reduction is proportional to the absolute risk so the higher the risk the greater the benefit. Thus adjuvant chemotherapy only achieves a meaningful benefit for patients with stage III and high risk stage II disease

The benefit from single agent Fu does not diminish with age although data is limited for patients over the age of 80. In contrast the benefit of the addition of oxaliplatin is questionable over the age of 70

Discussions with patients should include an estimate of the chances of benefit with single agent and combination adjuvant chemotherapy.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.